Sanofi Plans Amlitelimab Dermatitis Filing After New Readout

Why It Matters

A successful filing could give Sanofi a differentiated, less‑frequent biologic in a $10 billion AD market, while also offsetting future revenue loss from Dupixent’s patent expiry.

Key Takeaways

• Sanofi files AMLITELIMAB for atopic dermatitis after phase 3 data
• SHORE trial met primary endpoints; COAST 2 missed EASI‑75
• Dosing advantage: four times yearly vs Dupixent biweekly
• Investors skeptical due to unclear superiority over Dupixent
• Pipeline targets $11 billion sales by decade's end

Pulse Analysis

The global atopic dermatitis (AD) market continues to expand, driven by rising prevalence and demand for biologics that offer durable skin clearance. Sanofi’s amlitelimab, an anti‑OX40L antibody, represents a novel mechanism that modulates T‑cell activation without depleting the cells, positioning it as a potential alternative to the current standard, dupilumab (Dupixent). By branding amlitelimab as a ‘pipeline‑in‑a‑product,’ Sanofi signals its intent to diversify beyond its blockbuster Dupixent, especially as patent expiry looms in the early 2030s. The drug’s quarterly dosing schedule could address a key patient‑convenience gap.

In the latest read‑outs, the SHORE trial demonstrated statistically significant improvements on both vIGA‑AD and EASI‑75 at week 24, with some patients achieving clear or almost clear skin within two weeks of dosing. By contrast, COAST 2, which evaluated amlitelimab as monotherapy, met the vIGA‑AD endpoint but failed to reach significance on EASI‑75 and a secondary clear‑skin measure. The mixed outcomes underscore the importance of combination therapy with topical agents and raise questions about the antibody’s standalone potency relative to Dupixent’s established efficacy profile.

Investor sentiment remains cautious; the inability to demonstrate clear superiority over Dupixent dampens expectations for premium pricing. Nonetheless, Sanofi projects its trio of late‑stage immunology assets—amlitelimab, frexalimab, and SAR441566—to generate roughly $11 billion in annual revenue by 2030, offsetting the looming loss of Dupixent’s exclusivity. If the company can secure regulatory approval and leverage the four‑times‑yearly dosing advantage, amlitelimab could capture a niche of patients seeking less frequent injections, potentially expanding the overall biologics market share for AD therapies in the competitive landscape.